KW-6356
adenosine A2A antagonist / inverse agonist
KW-6356 (adenosine A2A antagonist / inverse agonist) is a cognitive & mood research compound. Selective adenosine A2A receptor antagonist AND inverse agonist. A2A receptors sit on the same striatal neurons as dopamine D2 and act as a brake on them; blocking A2A lifts that brake without stimulating dopamine receptors directly, which is why it does not carry the dyskinesia profile of dopaminergic drugs. The inverse-agonist part means it also suppresses A2A signalling that happens with no adenosine bound — a step beyond istradefylline, the approved A2A antagonist it is usually compared to.
KW-6356 quick facts
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | Not well characterised in public data |
| Forms | Oral |
| Evidence level | Human (Phase 2, Parkinson's — Kyowa Kirin) |
The most clinically advanced compound in this batch and the one Cam asked for by name. Studied as an adjunct in Parkinson's, not as a nootropic — the alertness effect people chase is the same mechanism caffeine uses at A2A, far more selectively. 3mg and 6mg were both run; 3mg had the better motor signal, so higher is not better on the trial's own data. Kyowa Kirin then discontinued the programme despite a positive readout, which means no phase 3 dose will ever exist. FORMAT: DA ships this as a 30ML ORAL LIQUID, not capsules — 5MG/ML by the spec block, so a 3mg dose is 0.6ML. Note their shop listing says 6MG/ML while the spec block says 5MG/ML; the spec block is used here, and at 6MG/ML a measured 0.6ML would deliver 3.6mg instead of 3mg. Measure by volume against the figure on the bottle you actually received.
How KW-6356 works
Selective adenosine A2A receptor antagonist AND inverse agonist. A2A receptors sit on the same striatal neurons as dopamine D2 and act as a brake on them; blocking A2A lifts that brake without stimulating dopamine receptors directly, which is why it does not carry the dyskinesia profile of dopaminergic drugs. The inverse-agonist part means it also suppresses A2A signalling that happens with no adenosine bound — a step beyond istradefylline, the approved A2A antagonist it is usually compared to.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
✅ Clinically validated
- Phase 2b, 503 patients, 24 weeks — placebo vs 3mg vs 6mg once daily as an adjunct to levodopa in Parkinson's, plus a 12-week phase 2a monotherapy study in early untreated patients. Both doses were tolerated; 3mg showed the greater trend toward motor improvement, so more was not better.
- Kyowa Kirin discontinued the programme despite the positive phase 2b readout. That is a commercial decision rather than a safety finding, but the practical consequence is that no phase 3 dose exists and none will.
📊 Correlative data
- The approved comparator, istradefylline, is a plain A2A antagonist and is licensed for OFF-episodes in Parkinson's. That drug's record is the closest thing to a read on what this class does over time.
🧪 Theoretical / extrapolated
- Adenosine A2A antagonist AND inverse agonist. A2A receptors sit on the same striatal neurons as dopamine D2 and act as a brake on them; blocking A2A lifts the brake without stimulating dopamine receptors directly.
- The inverse-agonist part also suppresses A2A signalling occurring with no adenosine bound — a step beyond a plain antagonist. Caffeine is a non-selective adenosine antagonist, which is why the subjective alertness people chase here is a far cruder version of the same lever.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
KW-6356 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- It blocks adenosine A2A receptors, and adenosine is the molecule that accumulates while you are awake and creates sleep pressure. Blocking A2A is the same axis caffeine acts on, far more selectively and for far longer. The first predicted problem is therefore the caffeine problem in a more durable form: insomnia, and a sleep debt you have removed your own ability to notice.
- A2A receptors sit on the same striatal neurons as dopamine D2 and act as a brake on them. Lifting that brake without stimulating D2 directly is the design intent — but the class's real-world experience says the brake still matters. Dyskinesia is the most common adverse effect of istradefylline, the approved A2A antagonist, at roughly 16–18% against 10% on placebo, in patients already taking levodopa.
- The rest of istradefylline's profile is the honest read-across for a compound in the same class: nausea, dizziness, constipation, insomnia, and hallucinations less commonly.
- Being an inverse agonist as well as an antagonist is a step beyond blockade — it suppresses A2A signalling that occurs with no adenosine bound at all. Nobody has characterised what removing that tonic signal does over years, because nobody has run it for years.
What has actually been reported
- Phase 2 in Parkinson's disease with a positive readout, and then a discontinued programme. So real human safety data does exist for this molecule — at the doses and durations of a Parkinson's adjunct trial, in Parkinson's patients taking levodopa. Not in healthy people using it for alertness, which is who is reading this.
- For the approved comparator, ALT elevations occurred in 4–11% against 5–6% on placebo — a small signal, but the baseline test is cheap enough that there is no reason not to have it.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Treat it as a long-acting stimulant for timing purposes — morning only, and count backwards from your bedtime rather than forwards from waking.
- Remember that it removes the feeling of sleep debt, not the debt. Adenosine keeps accumulating behind a blocked receptor. This is the mechanism by which an alertness compound quietly costs more than it delivers.
- If you smoke or vape nicotine, CYP1A induction is real and your exposure is not the same as a non-smoker's on the same amount.
- Track sleep objectively for the first fortnight. Self-report is the least reliable instrument available in precisely this situation, because the compound acts on the sense being used to report.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- A liver panel at baseline, for the modest transaminase signal seen with the approved compound in this class.
Don't run this if
- You take a strong CYP3A4 inhibitor or inducer. The class is cleared through CYP3A4 and CYP1A1 and is sensitive to both directions.
- You have a psychotic disorder or any history of hallucinations — hallucination is a recognised effect of the approved compound in this class.
- You already have a sleep problem, which describes most people shopping for an alertness compound in the first place.
The honest unknown
- The programme was discontinued for commercial reasons after a positive readout, so no phase 3 dose for this molecule will ever exist. That is a permanent gap rather than a temporary one, and it is the single most important thing to understand about the evidence base here — the missing data is not on its way.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get KW-6356
Buy KW-6356 at Disguised Alpha →KW-6356 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What KW-6356 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for KW-6356 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for KW-6356 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside KW-6356
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anaemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 102 markers A–Z
KW-6356 — frequently asked questions
What is KW-6356?
KW-6356 (adenosine A2A antagonist / inverse agonist) is a cognitive & mood research compound. Selective adenosine A2A receptor antagonist AND inverse agonist. A2A receptors sit on the same striatal neurons as dopamine D2 and act as a brake on them; blocking A2A lifts that brake without stimulating dopamine receptors directly, which is why it does not carry the dyskinesia profile of dopaminergic drugs. The inverse-agonist part means it also suppresses A2A signalling that happens with no adenosine bound — a step beyond istradefylline, the approved A2A antagonist it is usually compared to.
Where can I find KW-6356 dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full KW-6356 protocol are available to members inside the Academy. This public page covers what KW-6356 is, how it works and the evidence.
What is the half-life of KW-6356?
KW-6356 has an approximate half-life of Not well characterised in public data, which is part of what determines how often it's dosed.
What's the evidence behind KW-6356?
Current evidence level: Human (Phase 2, Parkinson's — Kyowa Kirin). KW-6356 is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact KW-6356 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →